Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lu AF11167 Modified Release Formulations
NCT02260830Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Aug 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Lu AF11167 in schizophrenia (2 arms), sponsored by Lundbeck. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to infinity and 7 more. Started Aug 2014; status: completed.
02
Drugs
Lu AF11167
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02260830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260830.